It has been also shown that the combination of imatinib and inhibitors of the MEK/ERK1/2 pathway may counteract the resistance to imatinib in CML cells [38, 39]. Here, MAP2K7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.